Russia’s Gamaleya National Research Center, known for developing Sputnik V, is preparing to launch human trials of an AI-designed personalized mRNA vaccine for melanoma in September–October 2025. This groundbreaking treatment uses artificial intelligence to rapidly analyze a patient's tumor genetics and develop a customized vaccine template within just one week.
Preclinical studies in animals have already shown strong results in reducing tumor growth and preventing its spread. The Phase I trials will begin in Moscow’s top oncology centers, focusing on melanoma first, with plans to expand to other cancers like pancreatic, kidney, and lung in the future.
The Russian government will cover the full cost of the $2,869-per-dose vaccine for its citizens, aiming to tackle the country’s 625,000 new cancer cases reported annually. This AI-driven approach could revolutionize cancer treatment and personalize care for thousands.